SCHEMBL315826

SCHEMBL315826

[CH2]NC(=O)c1cccc(C)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.69
HDAC6 Q9UBN7 1/20 0.69
SMN1; SMN2 Q16637 2/20 0.65
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
KCNK3 O14649 2/20 0.62
KCNK9 Q9NPC2 2/20 0.62
KCNH2 Q12809 1/20 0.62
PARP1 P09874 1/20 0.62
RXFP1 Q9HBX9 1/20 0.58
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
POLB P06746 2/20 0.57
TP53 P04637 1/20 0.57
MAPT P10636 1/20 0.56
CTDSP1 Q9GZU7 1/20 0.56
NT5E P21589 1/20 0.56
GRM5 P41594 1/20 0.54
TAS1R3 Q7RTX0 1/20 0.54
TAS1R1 Q7RTX1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24931248 0.83 SMN1; SMN2 (0.89) HDAC8HDAC6SMN1; SMN2MEN1KMT2A
SCHEMBL30929655 0.82 HDAC6 (1.00) HDAC8HDAC6SMN1; SMN2MEN1KMT2A
SCHEMBL5242529 0.82 HDAC6 (1.00) HDAC8HDAC6SMN1; SMN2MEN1KMT2A
SCHEMBL31540297 0.82 HDAC8 (0.71) HDAC8HDAC6SMN1; SMN2MEN1KMT2A
SCHEMBL82080 0.82 HDAC8 (0.71) HDAC8HDAC6SMN1; SMN2MEN1KMT2A
SCHEMBL9544991 0.80 SMN1; SMN2 (0.76) HDAC8HDAC6SMN1; SMN2MEN1KMT2A
SCHEMBL661545 0.80 HDAC8 (0.69) HDAC8HDAC6SMN1; SMN2MEN1KMT2A
SCHEMBL6459633 0.80 HDAC8 (0.69) HDAC8HDAC6SMN1; SMN2MEN1KMT2A
SCHEMBL4920155 0.80 HDAC8 (0.69) HDAC8HDAC6SMN1; SMN2MEN1KMT2A
SCHEMBL15109023 0.80 HDAC8 (0.69) HDAC8HDAC6SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093400-B2 Compounds useful in therapy PFIZER INC. (US) 2012-01-10 US disclosed
US-20100317652-A1 Compounds Useful In Therapy PFIZER INC 2010-12-16 US disclosed
US-7745630-B2 Triazolyl piperidine arginine vasopressin receptor modulators BRYANS JUSTIN STEPHEN 2010-06-29 US disclosed
US-20050154024-A1 Compounds useful in therapy PFIZER INC 2005-07-14 US disclosed
EP-1329160-A2 4-ACYLAMINOPYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154024-A1 Compounds useful in therapy PTGER4, PTGER3, ALOX5 HDAC8 836/4885HDAC6 2328/4885SMN1; SMN2 3508/4885
US-20100317652-A1 Compounds Useful In Therapy AVPR1A, AVPR1B, AVPR2 HDAC8 2054/4885HDAC6 1228/4885SMN1; SMN2 4519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.